Objective
To present the International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson9s disease.
Background
Although several diagnostic criteria for Parkinson9s disease have been proposed, none have been officially adopted by an official Parkinson society. Moreover, the commonest-used criteria, the UK brain bank, were created more than 25 years ago. In recognition of the lack of standard criteria, the MDS initiated a task force to design new diagnostic criteria for clinical Parkinson9s disease.
Methods/Results
The MDS-PD Criteria are intended for use in clinical research, but may also be used to guide clinical diagnosis. The benchmark is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise. Although motor abnormalities remain central, there is increasing recognition of non-motor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the MDS-PD Criteria retain motor parkinsonism as the core disease feature, defined as bradykinesia plus rest tremor and/or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies upon three categories of diagnostic features; absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of PD diagnosis). Two levels of certainty are delineated: Clinically-established PD (maximizing specificity at the expense of reduced sensitivity), and Probable PD (which balances sensitivity and specificity).
Conclusion
The MDS criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, criteria will need continuous revision to accommodate these advances. Disclosure: Dr. Postuma has received personal compensation for activities with Roche Diagnostics Corporation and Biotie Therapies. Dr. Berg has received research support from Michael J. Fox Foundation, the Bundesministerium fur Bildung und Forschung (BMBF), the German Parkinson Association and Novartis GmbH.

MDS Clinical Diagnostic Criteria for Parkinson's Disease (S19.001)

Here, published for the first time, are the complete proofs of the fundamental arithmetic duality theorems that have come to play an increasingly important role in number theory and arithmetic geometry. The text covers these theorems in Galois cohomology, tale cohomology, and flat cohomology and addresses applications in the above areas. The writing is expository and the book will serve as an invaluable reference text as well as an excellent introduction to the subject.

Arithmetic duality theorems

Advances in mathematics

We extend the results of [CHT] by removing the ‘minimal ramification’ condition on the lifts. That is we establish the automorphy of suitable conjugate self-dual, regular (de Rham with distinct Hodge–Tate numbers), l-adic lifts of certain automorphic mod l Galois representations of any dimension. The main innovation is a new approach to the automorphy of non-minimal lifts which is closer in spirit to the methods of [TW] than to those of [W], which relied on Ihara’s lemma.

/pdf/automorphy-for-some-l-adic-lifts-of-automorphic-mod-l-galois-1lron6w183.pdf

Automorphy for some l-adic lifts of automorphic mod l Galois representations

This book is designed as a text for the first year of graduate algebra, but it can also serve as a reference since it contains more advanced topics as well. This second edition has a different organization than the first. It begins with a discussion of the cubic and quartic equations, which leads into permutations, group theory, and Galois theory (for finite extensions; infinite Galois theory is discussed later in the book). The study of groups continues with finite abelian groups (finitely generated groups are discussed later, in the context of module theory), Sylow theorems, simplicity of projective unimodular groups, free groups and presentations, and the Nielsen-Schreier theorem (subgroups of free groups are free). The study of commutative rings continues with prime and maximal ideals, unique factorization, noetherian rings, Zorn's lemma and applications, varieties, and Grobner bases. Next, noncommutative rings and modules are discussed, treating tensor product, projective, injective, and flat modules, categories, functors, and natural transformations, categorical constructions (including direct and inverse limits), and adjoint functors. Then follow group representations: Wedderburn-Artin theorems, character theory, theorems of Burnside and Frobenius, division rings, Brauer groups, and abelian categories. Advanced linear algebra treats canonical forms for matrices and the structure of modules over PIDs, followed by multilinear algebra. Homology is introduced, first for simplicial complexes, then as derived functors, with applications to Ext, Tor, and cohomology of groups, crossed products, and an introduction to algebraic $K$-theory. Finally, the author treats localization, Dedekind rings and algebraic number theory, and homological dimensions. The book ends with the proof that regular local rings have unique factorization. (GSM/114)

/pdf/advanced-modern-algebra-xt5ld7apas.pdf

Advanced Modern Algebra

Part I Algebraic Theory: Cohomology of Profinite Groups.- Some Homological Algebra.- Duality Properties of Profinite Groups.- Free Products of Profinite Groups.- Iwasawa Modules.- Part II Arithmetic Theory: Galois Cohomology.- Cohomology of Local Fields.- Cohomology of Global Fields.- The Absolute Galois Group of a Global Field.- Restricted Ramification.- Iwasawa Theory of Number Fields.- Anabelian Geometry.- Literature.- Index.

Cohomology of number fields

Each year influenza epidemics cause a considerable burden of disease. Vaccination against influenza A and B viruses has been and remains the cornerstone of influenza prevention, but antiviral therapy can serve as an important adjunct to vaccination in controlling the impact of the disease. Two classes of drugs are currently licensed in a large number of countries for the treatment of influenza. The M2 ion channel blockers or amantadanes (amantadine and rimantadine) are specific inhibitors of influenza A virus replication, whereas the neuraminidase inhibitors (zanamivir and oseltamivir) are active against influenza A and B viruses. Readily transmissible drug-resistant viruses develop frequently during amantadane treatment but not during neuraminidase inhibitor treatment. In this review, efficacy and safety data from randomised controlled trials are evaluated to gain an understanding of what we can and cannot expect from antiviral treatment. All four drugs shorten the course of influenza disease by approximately 1 day and relieve symptoms to some extent, but there is still uncertainty as to whether antiviral therapy leads to a reduction of serious complications and hospitalisation. The results of cost-effectiveness analyses are very diverse, in part because of differences in methodology but also because there is no consensus on what probabilities to assign to the key risks and benefits that form the basis of these studies. Consensus statements by advisory bodies in England and Germany recommend neuraminidase inhibitors for the therapy of influenza in high-risk individuals such as people over 65 years or under 2 years, and individuals with chronic cardiovascular, pulmonary or renal disease, diabetes mellitus or immunosuppression. However, there is no agreement as to whether antiviral therapy can be generally recommended for otherwise healthy children and adults. The availability of safe and effective antiviral therapy options should be kept in mind by the practising clinician, while more specific recommendations and policy formulation will depend on additional efficacy data that include frequency of complications and hospitalisation as outcome measures.

/pdf/antiviral-therapy-for-influenza-a-clinical-and-economic-4bwxv0wvo1.pdf

Antiviral therapy for influenza : a clinical and economic comparative review.

Reverse genetics was used to develop a two-component, trivalent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncytial virus (RSV) subgroups A and B. The backbone for each of the two components of this vaccine was the attenuated recombinant bovine/human PIV3 (rB/HPIV3), a recombinant BPIV3 in which the bovine HN and F protective antigens are replaced by their HPIV3 counterparts (48). This chimera retains the well-characterized host range attenuation phenotype of BPIV3, which appears to be appropriate for immunization of young infants. The open reading frames (ORFs) for the G and F major protective antigens of RSV subgroup A and B were each placed under the control of PIV3 transcription signals and inserted individually or in homologous pairs as supernumerary genes in the promoter proximal position of rB/HPIV3. The level of replication of rB/HPIV3-RSV chimeric viruses in the respiratory tract of rhesus monkeys was similar to that of their parent virus rB/HPIV3, and each of the chimeras induced a robust immune response to both RSV and HPIV3. RSV-neutralizing antibody titers induced by rB/HPIV3-RSV chimeric viruses were equivalent to those induced by infection with wild-type RSV, and HPIV3-specific antibody responses were similar to, or slightly less than, after infection with the rB/HPIV3 vector itself. This study describes a novel vaccine strategy against RSV in which vaccine viruses with a common attenuated backbone, specifically rB/HPIV3 derivatives expressing the G and/or F major protective antigens of RSV subgroup A and of RSV subgroup B, are used to immunize by the intranasal route against RSV and HPIV3, which are the first and second most important viral agents of pediatric respiratory tract disease worldwide.

Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone

The notion of a tamely ramified covering is canonical only for curves. Several notions of tameness for coverings of higher dimensional schemes have been used in the literature. We show that all these definitions are essentially equivalent. Furthermore, we prove finiteness theorems for the tame fundamental groups of arithmetic schemes.

/pdf/on-different-notions-of-tameness-in-arithmetic-geometry-26rghfb0qr.pdf

Alexander Schmidt

Papers

Cohomology of number fields

Antiviral therapy for influenza : a clinical and economic comparative review.

Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone

On different notions of tameness in arithmetic geometry

On different notions of tameness in arithmetic geometry